Unknown OBSERVATIONAL NCT05792592

Small Airways Disease (SAD) in Severe Asthma as a Novel Endpoint and Distinct Target for Biological Therapy. (SASAB)

Small Airways Disease (SAD) in Severe Asthma as a Novel Endpoint and Distinct Target for Biological Therapy. Small Airways Disease (SAD) in Severe Asthma as a Novel Endpoint and Distinct Target for Biological Therapy (SASAB Study)

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Conditions Asthma Small Airway Disease

Interventions IOS (Impulse Oscillometry)

Updated 4 times since 2023 Last updated: Mar 19, 2023 Started: Feb 15, 2022 Primary completion: Dec 16, 2023 Completion: Jun 16, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Asthma and Small Airway Disease and is currently ongoing. Fondazione Policlinico Universitario Agostino Gemelli IRCCS leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Apr 2025 — Present [monthly]

Unknown

Status: Recruiting → Unknown
Sep 2024 — Apr 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Apr 2023 — Jul 2024 [monthly]

Recruiting

First recorded

Feb 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Data source: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Roma, Italy